OlarteMoure
With offices in Barranquilla, Bucaramanga, Cali and Medellín, as well as Bogotá, along with a presence in Tokyo, Japan, IP and competition boutique OlarteMoure offers both genuine national coverage and extensive regional and international capabilities. Noted for its ‘great teamwork’, the practice scores highly with sources for its ability to ’identify strategies to defend the client’s interests’. The group is primarily recognised for its patents prowess, where it frequently aligns with its top-notch life sciences department to handle a range of patent drafting, portfolio management, and contentious work. The practice also demonstrates great competency advise on trade marks, copyrights, anti-counterfeiting and technology transfer matters, among other areas. Names to note include patents head Carlos Olarte, who is highly regarded for his expertise in the biopharmaceutical and telecom spheres, and trade mark lead Juan Moure. Other experienced partners include patent specialist Alexander Agudelo and litigator Juan Felipe Acosta. The team additionally benefits from emerging expertise of directors María Alejandra Pava and Mónica Guevara, who handle trade marks and patents respectively. Since publication, the firm has promoted Liliana Galindo Díaz to head of patent litigation - effective as of April 2024.
Testimonials
Collated independently by Legal 500 research team.
‘The team's experience and expertise makes it unique. Lawyers have the ability to identify strategies to defend the client's interests. I identify with the firm's values when I see that they give team members opportunities for growth from a professional and academic point of view.’
‘We value the team for its great teamwork. Advice is coordinated and coherent. Lawyers demonstrate proactivity in the assigned matters.’
Key clients
- Ericsson
- Immatics Biotechnologies
Work highlights
- Represented Ericsson in standard essential patent infringement litigation against Apple.
- Prosecuted portfolios of patent applications in Latin America for Immatics Biotechnologies, Novartis, Merck, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb and Bayer Intellectual Property.